Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBW-012336 capsules in KRAS G12D-mutant advanced solid tumors (Phase I/II, China)
ChiCTR2500104588Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of HBW-012336 in Nonhematologic neoplasms, pancreatic cancer (PC), colorectal cancer (CRC) and 2 more (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Safety and tolerability, Maximum tolerated dose (MTD) and 2 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
HBW-012336
03
Conditions
Nonhematologic neoplasmspancreatic cancer (PC)colorectal cancer (CRC)bronchial carcinomaendometrial cancer (EC)
Beyond the preview
Go deeper on ChiCTR2500104588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104588.